

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-8 (canceled)

9. (currently amended) A method of using a proline specific endoprotease to hydrolyse at a pH of below 5.5, proline rich peptides which are brought with celiac disease, a disease associated with the occurrence of celiac disease, or a disease caused by a decreased level in a patient's body of proline specific proteases required for breakdown of these peptides, the method comprising administering a dietary supplement or a medicament comprised of said proline specific endoprotease for ingestion by a patient in need thereof, whereby the proline specific endoprotease is active in the stomach and is pepsin resistant.

10. (canceled)

11. (currently amended) A method of using a proline specific endoprotease having a pH optimum below 6.5, the method comprising administering said proline specific endoprotease for ingestion by a patient in need thereof, whereby the patient suffers from celiac disease, a disease associated with the occurrence of celiac disease, or a disease caused by a decreased level in the patient's body of proline specific

proteases, and whereby the proline specific endoprotease is active in the stomach and is pepsin resistant.

12. (previously presented) The method according to claim 11, wherein the proline specific endoprotease is an *Aspergillus* enzyme.

13-22. (canceled)

23. (previously presented) The method according to claim 9, wherein the proline specific endoprotease is an *Aspergillus* enzyme.

24. (previously presented) The method according to claim 9, wherein the proline specific endoprotease is an *Aspergillus niger* enzyme.

25. (previously presented) The method according to claim 10, wherein the proline specific endoprotease is an *Aspergillus* enzyme.

26. (previously presented) The method according to claim 10, wherein the proline specific endoprotease is an *Aspergillus niger* enzyme.

27. (previously presented) The method according to claim 11, wherein the proline specific endoprotease is an *Aspergillus niger* enzyme.

28. (previously presented) The method according to claim 9, wherein the patient suffers from celiac disease.

29. (previously presented) The method according to claim 11, wherein the patient suffers from celiac disease.

30. (previously presented) The method according to claim 9, wherein the patient is gluten sensitive.

31. (previously presented) The method according to claim 11, wherein the patient is gluten sensitive.